JUN 04, 2020 3:30 AM PDT

Inhibiting the Signals Critical for Cancer Growth in Merkel Cell Carcinoma

WRITTEN BY: Jasper Cantrell

Merkel Cell Carcinoma (MCC) is a highly aggressive cancer of the skin. It is characterized by a high recurrence rate and a very poor five-year prognosis. Drugs targeting the programmed cell death protein 1 (PD1) have had recent success as an FDA approved drug. However, fifty percent of patients do not respond to this treatment. A new method utilizing a two-pronged approach has been proposed; using immunotherapy and targeted drug therapy together as a treatment. Unfortunately, MCC does not have any FDA targeted therapies yet.

One possibility for a targeted therapy that has seen success in other cancers is using a phosphoinositide-3-kinase (PI3K) inhibitor. The PI3K/Akt/mTOR pathway is critical in many cellular processes such as cellular proliferation and survival. They are often de-regulated in many cancers, and can promote unregulated tumor growth. Genomic studies have revealed that this pathway is abnormally activated in MCC. PI3K has several isoforms, or variants, and pan-PI3K inhibitors have been shown to have toxic side effects. The PI3K-delta isoform targeting idelalisib has had surprising success in treating stage IV MCC in one instance. A team from Arkansas decided to follow up on this finding and see if any other isoform targeting PI3K inhibitors could be used to treat MCC.

The team analyzed the expression of the different isoforms of PI3K in several MCC archived tissues from their library and found that PI3K-delta was the most common isoform showing up in 52% of the tissues tested. The next closest was PI3K-alpha, found in 30% of the tissues. Choosing four MCC cell lines, each with a different isoform expression. The team then applied one of four PI3K isoform inhibitors to identify the effects they would have on growth. Each MCC cell line had a slightly different response, but the PI3K alpha/delta inhibitor copanlisib produced the best and most consistent suppression of proliferation. Examining the effect of the inhibitors on apoptosis of the MCC cell lines showed that while all inhibitors induced apoptosis to some degree, copanlisib again produced the most robust response. Copansilib continued to outperform even the successful idelalisib. A final mouse experiment using xenografts or MCC cell lines or patients into mice showed that copansilib managed to impair tumor growth with no apparent signs of toxicity.

The need for alternative therapies for MCC is clear, with the poor prognosis and high recurrence if the current available PD1 treatment. Inhibitors of the PI3K/Akt/mTOR pathway have exhibited potential in several other studies in other cancers, and early work continues this trend. Copansilib is shown to be more effective than other inhibitors at low concentrations, effectively impairing the growth of MCC tumors in mice. The mechanism of action still needs to be investigated, but never-the-less PI3K isoform inhibitors have proven themselves to be effective against cancer growth.

Sources: Nature, OncLiveTV
 

About the Author
  • Hey everyone! My name is Jasper and, considering I am pretty new here to Labroots, I figured I would introduce myself. I received my bachelor’s from the University of California at Riverside back in 2016. I started off my career a few years ago with a job at a University over in New York, before moving over into the industry. I'm happy to be writing content for Labroots, and I hope you enjoy it!
You May Also Like
MAY 26, 2020
Cancer
Does having a child with cancer increase parents' risk of divorce?
MAY 26, 2020
Does having a child with cancer increase parents' risk of divorce?
A study from Denmark published in the American Cancer Society journal CANCER reports that having a child with cancer doe ...
JUN 05, 2020
Cancer
Diet can influence effectiveness of chemotherapy
JUN 05, 2020
Diet can influence effectiveness of chemotherapy
Can changing your diet improve chemotherapy results? New research published in Nature Communications suggests that diet- ...
JUL 01, 2020
Cancer
The MicroRNA That Can Regulate Tumor Vascularization in Liver Cancer
JUL 01, 2020
The MicroRNA That Can Regulate Tumor Vascularization in Liver Cancer
Angiogenesis is the vascularization, or generation of blood vessels, of a part of the body. It is a normal function of h ...
JUL 16, 2020
Immunology
Cancer Vaccine Charges Toward the Clinic
JUL 16, 2020
Cancer Vaccine Charges Toward the Clinic
Kristen Radford, a professor at Australia’s University of Queensland is among a scientific research team developin ...
JUL 17, 2020
Cancer
Tackling the Problem of Toxicity in Breast Cancer Therapy
JUL 17, 2020
Tackling the Problem of Toxicity in Breast Cancer Therapy
Chemotherapy has been one of the primary methods of cancer treatment for decades. Usually, a doctor applies a chemothera ...
AUG 03, 2020
Cell & Molecular Biology
Gut Microbes & Diet Change the Behavior of a Cancer-Driving Protein
AUG 03, 2020
Gut Microbes & Diet Change the Behavior of a Cancer-Driving Protein
Clinicians and researchers have long wondered why cancer is the small intestine is rare while it's so common in the colo ...
Loading Comments...